Vulvar erosions in a young girl

doi: 10.1111/pde.15284.

Online ahead of print.


Item in Clipboard

Ana Taibo et al.

Pediatr Dermatol.


No abstract available


bullous disease-immunologic; dermatopathology; immunobullous disease; mucous membrane disorders.



    1. Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445-455. doi:10.1016/j.autrev.2017.03.010

    1. Oranje AP, Van Joost T. Pemphigoid in children. Pediatr Dermatol. 1989;6(4):267-274. doi:10.1111/j.1525-1470.1989.tb00910.x

    1. Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513-528. doi:10.1007/s40257-017-0264-2

    1. DeCastro P, Jorizzo JL, Rajaraman S, Solomon AR, Briggaman RA, Raimer SS. Localized vulvar pemphigoid in a child. Pediatr Dermatol. 1985;2(4):302-307. doi:10.1111/j.1525-1470.1985.tb00470.x

    1. Farrell AM, Kirtschig G, Dalziel KL, et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol. 1999;140(2):308-312. doi:10.1046/j.1365-2133.1999.02668.x

Source link

Study protocol for a phase 1, randomised, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of ascending topical doses of TCP-25 applied to epidermal suction blister wounds in healthy male and female volunteers


TCP-25 gel is intended for use in treatment of wound infection and inflammation. Current local therapies for wounds have limited efficacy to prevent infections and there are no wound treatments available today that target the excessive inflammation that often hampers wound healing in both acute and chronic wounds. There is therefore a high medical need for new therapeutic alternatives.

Methods and analysis:

A randomised, double-blinded, first-in-human study was designed to evaluate the safety, tolerability and potential systemic exposure of three increasing doses of the TCP-25 gel applied topically on suction blister wounds in healthy adults. The dose-escalation will be divided into three sequential dose groups with eight subjects in each group (24 patients in total). Within each dose group, the subjects will receive four wounds, with two wounds on each thigh. Each subject will receive TCP-25 on one wound per thigh and placebo on one wound per thigh in a randomised double-blinded manner, with a reverse reciprocal position on each respective thigh, to a total of five doses over 8 days. An internal safety review committee will monitor emerging safety and plasma concentration data over the course of the study and must give a favourable recommendation prior to initiating the next dose group, which will receive placebo gel or a higher concentration of TCP-25 in exactly the same manner described above.

Ethics and dissemination:

The study will be performed in accordance with ethical principles consistent with the Declaration of Helsinki, ICH/GCPE6 (R2), European Union Clinical Trials Directive and applicable local regulatory requirements.This study is approved by the Swedish Medical Products Agency and the Swedish ethics committee under the registration number 2022-00527-01. The results of this study will be disseminated via publication to a peer-reviewed journal at the discretion of the Sponsor.

Trial registration number:




Source link